NeuroRx: Developing first Glx targeted antidepressant to address suicidality in bipolar depression. Lead candidate, NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. Reported Ph 2 efficacy and safety data for NRX-011 in Dec 18, suggesting potential for NRX-101 in maintaining remission from several bipolar depression with acute suicidal ideation following an initial stabilization with ketamine. Co is also leading Relief Therapeutics’ Ph 2 trial of Aviptadil to treat COVID-19 induced ARDS in the US.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase III
Disease Space
Central Nervous System
Industry
Biotechnology
Listing
Private
Market Cap
Private
Website:
Profiles:
Address:
913 North Market Street
Suite 200
Wilmington, DE 19801
United States

Company Participants at Solebury Trout KOL Day

  • Robert Besthof, CMO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Fall Private Company Showcase 2020

VIRTUAL, October 15, 2020